Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes.

[en] Dipeptidyl peptidase-4 inhibitors (DPP-4is) and sodium-glucose cotransporter type 2 inhibitors (SGLT2is) offer new options for the oral management of type 2 diabetes mellitus (T2DM), with the advantage in the elderly population to be devoid of a high risk of hypoglycaemia. SGLT2is have also shown benefits regarding cardiovascular (heart failure) and renal protection, including in patients with T2DM aged ≥ 65 years while DPP-4is have only proved cardiovascular and renal safety without superiority compared with placebo. The glucose-lowering efficacy of the two pharmacological classes is almost similar including in older patients with T2DM. However, the tolerance and safety profile may be highly different and overall more favourable with DPP-4is than with SGLT2is. Some adverse events have been reported with SGLT2is which may be more prevalent or severe in older patients than in younger patients. The present comprehensive review focuses on the benefit/risk balance in the elderly population with T2DM by comparing the profile of DPP-4is and SGLT2is regarding the following potential issues: metabolic disorders (hypoglycaemia and diabetic ketoacidosis); cardiac and vascular issues (atheromatous cardiovascular disease, heart failure, volume reduction hypotension, and lower limb amputations); renal endpoints including acute renal injury; risk of infections; digestive disorders; bone and skin adverse events; and cancer risk. Both DPP-4is and SGLT2is have their own advantages and disadvantages. Personalised treatment is recommended based upon the efficacy/safety profile of each drug class and individual patient characteristics that may be markedly different among the heterogeneous population of older individuals with T2DM.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Efficacy / safety balance of DPP-4 inhibitors versus SGLT2 inhibitors in elderly patients with type 2 diabetes.

Publication date :

2021

Journal title :

Diabetes & metabolism

ISSN :

1262-3636

eISSN :

1878-1780

Volume :

Issue :

Pages :

101275

Peer reviewed :

Peer reviewed

Commentary :

Available on ORBi :

since 19 October 2021

Statistics

Number of views

59 (1 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

American Diabetes Association. 12. Older adults: standards of medical care in diabetes-2021. Diabetes Care 44 (2021), S168–SS79.
Sinclair, A, Morley, JE, Rodriguez-Manas, L, Paolisso, G, Bayer, T, Zeyfang, A, et al. Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 13 (2012), 497–502.
Diabetes Canada Clinical Practice Guidelines Expert Committee Meneilly, GS, Knip, A, Miller, DB, Sherifali, D, Tessier, D, et al. Diabetes in older people. Can J Diabetes 42:Suppl 1 (2018), S283–SS95.
LeRoith, D, Biessels, GJ, Braithwaite, SS, Casanueva, FF, Draznin, B, Halter, JB, et al. Treatment of diabetes in older adults: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104 (2019), 1520–1574.
Mooradian, AD., Evidence-based management of diabetes in older adults. Drugs Aging 35 (2018), 1065–1078.
Scheen, AJ., Non-insulin-dependent diabetes mellitus in the elderly. Baillieres Clin Endocrinol Metab 11 (1997), 389–406.
Schernthaner, G, Schernthaner-Reiter, MH., Diabetes in the older patient: heterogeneity requires individualisation of therapeutic strategies. Diabetologia 61 (2018), 1503–1516.
Scheen, AJ, Lefebvre, PJ., Oral antidiabetic agents. A guide to selection. Drugs 55 (1998), 225–236.
Scheen, AJ., Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opin Pharmacother 2021 (2021 Apr 13), 1–17, 10.1080/14656566.2021.1912735.
Scheen, AJ., The safety of gliptins: updated data in 2018. Expert Opin Drug Saf 17 (2018), 387–405.
Paolisso, G, Monami, M, Marfella, R, Rizzo, MR, Mannucci, E., Dipeptidyl peptidase-4 inhibitors in the elderly: more benefits or risks?. Adv Ther 29 (2012), 218–233.
Barzilai, N, Guo, H, Mahoney, EM, Caporossi, S, Golm, GT, Langdon, RB, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin 27 (2011), 1049–1058.
Round, EM, Engel, SS, Golm, GT, Davies, MJ, Kaufman, KD, Goldstein, BJ., Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies. Drugs Aging 31 (2014), 203–214.
Tago, M, Oyama, JI, Sakamoto, Y, Shiraki, A, Uchida, F, Chihara, A, et al. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. Geriatr Gerontol Int 18 (2018), 631–639.
Bluher, M, Kurz, I, Dannenmaier, S, Dworak, M., Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study. World J Diabetes 3 (2012), 161–169.
Strain, WD, Lukashevich, V, Kothny, W, Hoellinger, MJ, Paldanius, PM., Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 382 (2013), 409–416.
Schweizer, A, Dejager, S., Experience with vildagliptin in patients >/=75 years with type 2 diabetes and moderate or severe renal impairment. Diabetes Ther 4 (2013), 257–267.
Pratley, RE, Rosenstock, J, Pi-Sunyer, FX, Banerji, MA, Schweizer, A, Couturier, A, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. Diabetes Care 30 (2007), 3017–3022.
Karyekar, CS, Ravichandran, S, Allen, E, Fleming, D, Frederich, R, Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged >/= 65 years) with inadequately controlled type 2 diabetes mellitus. Clin Interv Aging 8 (2013), 419–430.
Iqbal, N, Allen, E, Ohman, P., Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged >/= 65 years) with type 2 diabetes. Clin Interv Aging 9 (2014), 1479–1487.
Barnett, AH, Huisman, H, Jones, R, von Eynatten, M, Patel, S, Woerle, HJ., Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial. Lancet 382 (2013), 1413–1423.
Schernthaner, G, Barnett, AH, Patel, S, Hehnke, U, von Eynatten, M, Woerle, HJ., Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged >/= 65 years. Diabetes Obes Metab 16 (2014), 1078–1086.
Rosenstock, J, Wilson, C, Fleck, P., Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study. Diabetes Obes Metab 15 (2013), 906–914.
Bron, M, Wilson, C, Fleck, P., A post hoc analysis of HbA1c, hypoglycemia, and weight change outcomes with alogliptin vs glipizide in older patients with type 2 diabetes. Diabetes Ther 5 (2014), 521–534.
Kadowaki, T, Haneda, M, Ito, H, Sasaki, K, Yamada, Y., Long-term safety and efficacy of teneligliptin in elderly patients with type 2 diabetes: subgroup analysis of a 3-year post-marketing surveillance in Japan. Adv Ther 37 (2020), 2477–2492.
Scheen, AJ., Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res 122 (2018), 1439–1459.
Scheen, AJ., Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
Buse, JB, Wexler, DJ, Tsapas, A, Rossing, P, Mingrone, G, Mathieu, C, et al. 2019 update to: management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 63 (2020), 221–228.
Scheen, AJ., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16 (2020), 556–577.
Giugliano, D, Longo, M, Maiorino, MI, Bellastella, G, Chiodini, P, Solerte, SB, et al. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract, 162, 2020, 108114.
Scheen, AJ., An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 18 (2019), 295–311.
Kinduryte Schorling, O, Clark, D, Zwiener, I, Kaspers, S, Lee, J, Iliev, H, Pooled safety and tolerability analysis of empagliflozin in patients with type 2 diabetes mellitus. Adv Ther 37 (2020), 3463–3484.
Fioretto, P, Mansfield, TA, Ptaszynska, A, Yavin, Y, Johnsson, E, Parikh, S., Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb/III studies. Drugs Aging 33 (2016), 511–522.
Sinclair, AJ, Bode, B, Harris, S, Vijapurkar, U, Shaw, W, Desai, M, et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc 64 (2016), 543–552.
Pratley, R, Dagogo-Jack, S, Charbonnel, B, Patel, S, Hickman, A, Liu, J, et al. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: a pooled analysis of phase III studies. Diabetes Obes Metab 22 (2020), 2276–2286.
Yokote, K, Terauchi, Y, Nakamura, I, Sugamori, H., Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study. Expert Opin Pharmacother 17 (2016), 1995–2003.
Cahn, A, Mosenzon, O, Wiviott, SD, Rozenberg, A, Yanuv, I, Goodrich, EL, et al. Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study. Diabetes Care 43 (2020), 468–475.
Monteiro, P, Bergenstal, RM, Toural, E, Inzucchi, SE, Zinman, B, Hantel, S, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. Age Ageing 48 (2019), 859–866.
Pratley, RE, Dagogo-Jack, S, Charbonnel, B, Cherney, D, Cosentino, F, MD, K., et al. Ertugliflozin in older patients with type 2 diabetes (T2DM): an analysis from VERTIS CV (abstract). Diabetes, 70, 2021, 791-P https://doi.org/10.2337/db21-791-P).
Yabe, D, Shiki, K, Suzaki, K, Meinicke, T, Kotobuki, Y, Nishida, K, et al. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes. BMJ Open, 11, 2021, e045844.
Wang, Z, Sun, J, Han, R, Fan, D, Dong, X, Luan, Z, et al. Efficacy and safety of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors as monotherapy or add-on to metformin in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab 20 (2018), 113–120.
Min, SH, Yoon, JH, Hahn, S, Cho, YM., Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev, 33, 2017, 10.1002/dmrr.2818.
Scheen, AJ., SGLT2 versus DPP4 inhibitors for type 2 diabetes. Lancet Diabetes Endocrinol 1 (2013), 168–170.
Scheen, AJ., Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: a systematic review of randomized controlled trials. Diabetes Metab 46 (2020), 186–196.
Scheen, AJ., Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14 (2015), 505–524.
Ujihara, N, Sakura, H, Hashimoto, N, Sasamoto, K, Ohashi, H, Hasumi, S, et al. Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus and comparison of hypoglycemic action of concomitant medications: a subanalysis of the JAMP study. Diabetol Int 9 (2018), 56–65.
Terauchi, Y, Yamada, Y, Ishida, H, Ohsugi, M, Kitaoka, M, Satoh, J, et al. Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged >/= 60 years (START-J trial). Diabetes Obes Metab 19 (2017), 1188–1192.
Umezawa, S, Kubota, A, Maeda, H, Kanamori, A, Matoba, K, Jin, Y, et al. Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: post hoc analysis of the ASSET-K study. BMC Endocr Disord, 15, 2015, 34.
Tada, Y, Kanazawa, I, Notsu, M, Tanaka, K, Kiyohara, N, Sasaki, M, et al. Long-term efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus. Intern Med 55 (2016), 1275–1278.
Lee, S, Lee, H, Kim, Y, Kim, E., Effect of DPP-IV inhibitors on glycemic variability in patients with T2DMM: a systematic review and meta-analysis. Sci Rep, 9, 2019, 13296.
Nomoto, H, Miyoshi, H, Sugawara, H, Ono, K, Yanagiya, S, Oita, M, et al. A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin. Diabetol Metab Syndr, 9, 2017, 54.
Fuchigami, A, Shigiyama, F, Kitazawa, T, Okada, Y, Ichijo, T, Higa, M, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol, 19, 2020, 1.
Scheen, AJ., Cardiovascular effects of gliptins. Nat Rev Cardiol 10 (2013), 73–84.
Scheen, AJ., Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure. Curr Cardiol Rep, 21, 2019, 70.
Scheen, AJ., Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Res Clin Pract 121 (2016), 204–214.
Scheen, AJ, Delanaye, P., Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: focus on SGLT2 inhibitors and EMPA-REG OUTCOME. Diabetes Metab 43 (2017), 99–109.
Oliveros, E, Patel, H, Kyung, S, Fugar, S, Goldberg, A, Madan, N, et al. Hypertension in older adults: assessment, management, and challenges. Clin Cardiol 43 (2020), 99–107.
Shao, SC, Chang, KC, Lin, SJ, Chien, RN, Hung, MJ, Chan, YY, et al. Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients. Cardiovasc Diabetol, 19, 2020, 17.
Cha, SA, Park, YM, Yun, JS, Lim, TS, Song, KH, Yoo, KD, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis, 16, 2017, 58.
Bailey, CJ., Uric acid and the cardio-renal effects of SGLT2 inhibitors. Diabetes Obes Metab 21 (2019), 1291–1298.
Bonnet, F, Scheen, AJ., Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: potential contribution for diabetic complications and cardiovascular disease. Diabetes Metab 44 (2018), 457–464.
Mulvihill, EE, Drucker, DJ., Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev 35 (2014), 992–1019.
Zhang, Y, Hong, J, Chi, J, Gu, W, Ning, G, Wang, W, Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials. Diabetes Metab Res Rev 30 (2014), 241–256.
Mishriky, BM, Cummings, DM, Tanenberg, RJ., The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract 109 (2015), 378–388.
Deacon, CF, Lebovitz, HE., Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas. Diabetes Obes Metab 18 (2016), 333–347.
Ou, SM, Shih, CJ, Chao, PW, Chu, H, Kuo, SC, Lee, YJ, et al. Effects on clinical outcomes of adding dipeptidyl peptidase-4 inhibitors versus sulfonylureas to metformin therapy in patients with type 2 diabetes mellitus. Ann Intern Med 163 (2015), 663–672.
Eriksson, JW, Bodegard, J, Nathanson, D, Thuresson, M, Nystrom, T, Norhammar, A., Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract 117 (2016), 39–47.
Fukuda, M, Doi, K, Sugawara, M, Mochizuki, K., Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: a focus on hypoglycemia. J Diabetes Investig 10 (2019), 383–391.
Nauck, M, Araki, A, Hehnke, U, Plat, A, Clark, D, Khunti, K., Risk of hypoglycaemia in people aged >/=65 years receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. Int J Clin Pract, 72, 2018, e13240.
Inzucchi, SE, Nauck, MA, Hehnke, U, Woerle, HJ, von Eynatten, M, Henry, RR., Improved glucose control with reduced hypoglycaemic risk when linagliptin is added to basal insulin in elderly patients with type 2 diabetes. Diabetes Obes Metab 17 (2015), 868–877.
Zullo, AR, Smith, RJ, Gutman, R, Kohler, B, Duprey, MS, Berry, SD, et al. Comparative safety of dipeptidyl peptidase-4 inhibitors and sulfonylureas among frail older adults. J Am Geriatr Soc, 2021, 10.1111/jgs.17371 Jul 21.
Espeland, MA, Pratley, RE, Rosenstock, J, Kadowaki, T, Seino, Y, Zinman, B, et al. Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial. Diabetes Obes Metab 23 (2021), 569–580.
Ledesma, G, Umpierrez, GE, Morley, JE, Lewis-D'Agostino, D, Keller, A, Meinicke, T, et al. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: a randomized trial. Diabetes Obes Metab 21 (2019), 2465–2473.
Bethel, MA, Engel, SS, Green, JB, Huang, Z, Josse, RG, Kaufman, KD, et al. Assessing the safety of sitagliptin in older participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes Care 40 (2017), 494–501.
Leiter, LA, Teoh, H, Braunwald, E, Mosenzon, O, Cahn, A, Kumar, KM, et al. Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. Diabetes Care 38 (2015), 1145–1153.
Cooper, ME, Rosenstock, J, Kadowaki, T, Seino, Y, Wanner, C, Schnaidt, S, et al. Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: a prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA(R) trial. Diabetes Obes Metab 22 (2020), 1062–1073.
Custodio, JS Jr., Roriz-Filho, J, Cavalcanti, CAJ, Martins, A, Salles, JEN, Use of SGLT2 inhibitors in older adults: scientific evidence and practical aspects. Drugs Aging 37 (2020), 399–409.
Ueda, P, Svanstrom, H, Melbye, M, Eliasson, B, Svensson, AM, Franzen, S, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ, 363, 2018, k4365.
Han, SJ, Ha, KH, Lee, N, Kim, DJ., Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diabetes Obes Metab 23 (2021), 682–691.
Douros, A, Lix, LM, Fralick, M, Dell'Aniello, S, Shah, BR, Ronksley, PE, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study. Ann Intern Med 173 (2020), 417–425.
Fralick, M, Schneeweiss, S, Patorno, E., Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 376 (2017), 2300–2302.
Cefalu, WT, Kaul, S, Gerstein, HC, Holman, RR, Zinman, B, Skyler, JS, et al. Cardiovascular outcomes trials in type 2 diabetes: where do we go from here? Reflections from a Diabetes Care Editors' Expert Forum. Diabetes Care 41 (2018), 14–31.
Gordon, J, McEwan, P, Evans, M, Puelles, J, Sinclair, A., Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care-based cohort study, with economic assessment of patient outcomes. Diabetes Obes Metab 19 (2017), 644–653.
Scheen, AJ., Cardiovascular safety of DPP-4 inhibitors compared with sulphonylureas: results of randomized controlled trials and observational studies. Diabetes Metab 44 (2018), 386–392.
Rosenstock, J, Kahn, SE, Johansen, OE, Zinman, B, Espeland, MA, Woerle, HJ, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA 322 (2019), 1155–1166.
Karagiannis, T, Tsapas, A, Athanasiadou, E, Avgerinos, I, Liakos, A, Matthews, DR, et al. GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: a systematic review and meta-analysis. Diabetes Res Clin Pract, 174, 2021, 108737.
Persson, F, Nystrom, T, Jorgensen, ME, Carstensen, B, Gulseth, HL, Thuresson, M, et al. Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in type 2 diabetes patients (CVD-REAL Nordic) when compared to DPP-4 inhibitors: a multinational observational study. Diabetes Obes Metab 20 (2018), 344–351.
Gautam, S, Agiro, A, Barron, J, Power, T, Weisman, H, White, J., Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol, 16, 2017, 93.
Filion, KB, Lix, LM, Yu, OH, Dell'Aniello, S, Douros, A, Shah, BR, et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, 370, 2020, m3342.
Fralick, M, Colacci, M, Thiruchelvam, D, Gomes, T, Redelmeier, DA., Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a nationwide cohort study of older adults with diabetes mellitus. Diabetes Obes Metab 23 (2021), 950–960.
Kohsaka, S, Lam, CSP, Kim, DJ, Cavender, MA, Norhammar, A, Jorgensen, ME, et al. Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study. Lancet Diabetes Endocrinol 8 (2020), 606–615.
Komuro, I, Kadowaki, T, Bodegard, J, Thuresson, M, Okami, S, Yajima, T., Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases. Diabetes Obes Metab 23 Suppl:2 (2021), 19–27.
Idris, I, Zhang, R, Mamza, JB, Ford, M, Morris, T, Banerjee, A, et al. Lower risk of hospitalisation for heart failure, kidney disease and death with sodium glucose co-transporter-2 compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care. Diabetes Obes Metab 23 (2021), 2207–2214.
Birkeland, KI, Bodegard, J, Banerjee, A, Kim, DJ, Norhammar, A, Eriksson, JW, et al. Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: a large multinational observational study. Diabetes Obes Metab 23 (2021), 75–85.
Suto, G, Molnar, GA, Rokszin, G, Fabian, I, Kiss, Z, Szekanecz, Z, et al. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study. BMJ Open Diabetes Res Care, 9, 2021, e001765.
Singh, AK, Singh, R., Heart failure hospitalization with DPP-4 inhibitors: a systematic review and meta-analysis of randomized controlled trials. Indian J Endocrinol Metab 23 (2019), 128–133.
Cobretti, MR, Bowman, B, Grabarczyk, T, Potter, E., Dipeptidyl peptidase-4 inhibitors and heart failure exacerbation in the Veteran population: an observational study. Pharmacotherapy 38 (2018), 334–340.
Yin, D, Qiu, M, Wei, X, Duan, X., Meta-analyzing the factors affecting the efficacy of gliflozins in patients with heart failure based on heart failure trials. Medicine, 100, 2021, e26561.
Ling, AW, Chan, CC, Chen, SW, Kao, YW, Huang, CY, Chan, YH, et al. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors. Cardiovasc Diabetol, 19, 2020, 188.
Vrachatis, DA, Papathanasiou, KA, Iliodromitis, KE, Giotaki, SG, Kossyvakis, C, Raisakis, K, et al. Could sodium/glucose co-transporter-2 inhibitors have antiarrhythmic potential in atrial fibrillation? Literature review and future considerations. Drugs 81 (2021), 1381–1395.
Chang, CC, Chen, YT, Hsu, CY, Su, YW, Chiu, CC, Leu, HB, et al. Dipeptidyl peptidase-4 inhibitors, peripheral arterial disease, and lower extremity amputation risk in diabetic patients. Am J Med 130 (2017), 348–355.
Lee, HF, Chen, SW, Liu, JR, Li, PR, Wu, LS, Chang, SH, et al. Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor. Cardiovasc Diabetol, 19, 2020, 160.
Potier, L, Roussel, R, Velho, G, Saulnier, PJ, Bumbu, A, Matar, O, et al. Lower limb events in individuals with type 2 diabetes: evidence for an increased risk associated with diuretic use. Diabetologia 62 (2019), 939–947.
Alshnbari, A, Alkharaiji, M, Anyanwagu, U, Idris, I., Diuretics and risk of lower extremity amputation amongst patients with insulin-treated type 2 diabetes - exploring the mechanism of possible sodium glucose co-transporter 2 inhibitor induced risk of lower extremity amputations. Curr Med Res Opin 36 (2020), 1985–1989.
Huang, CY, Lee, JK., Sodium-glucose co-transporter-2 inhibitors and major adverse limb events: a trial-level meta-analysis including 51 713 individuals. Diabetes Obes Metab 22 (2020), 2348–2355.
Chang, HY, Singh, S, Mansour, O, Baksh, S, Alexander, GC., Association between sodium-glucose cotransporter 2 inhibitors and lower extremity amputation among patients with type 2 diabetes. JAMA Intern Med 178 (2018), 1190–1198.
Yang, JY, Wang, T, Pate, V, Gower, EW, Crowley, MJ, Buse, JB, et al. Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: evolving questions, evolving answers. Diabetes Obes Metab 21 (2019), 1223–1236.
Scheen, AJ., Does lower-limb amputation concern all SGLT-2 inhibitors ?. Nature Rev Endocrinol 14 (2018), 326–328.
Fralick, M, Kim, SC, Schneeweiss, S, Everett, BM, Glynn, RJ, Patorno, E., Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ, 370, 2020, m2812.
Yu, OHY, Dell'Aniello, S, Shah, BR, Brunetti, VC, Daigle, JM, Fralick, M, et al. Sodium-glucose cotransporter 2 inhibitors and the risk of below-knee amputation: a multicenter observational study. Diabetes Care 43 (2020), 2444–2452.
Rehman, MB, Tudrej, BV, Soustre, J, Buisson, M, Archambault, P, Pouchain, D, et al. Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: meta-analysis of placebo-controlled randomized clinical trials. Diabetes Metab 43 (2017), 48–58.
Cooper, ME, Perkovic, V, McGill, JB, Groop, PH, Wanner, C, Rosenstock, J, et al. Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes. Am J Kidney Dis 66 (2015), 441–449.
Rosenstock, J, Perkovic, V, Johansen, OE, Cooper, ME, Kahn, SE, Marx, N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 321 (2018), 69–79.
Shih, CJ, Lee, YJ, Lo, YH, Kuo, SC, Ou, SM, Chen, YT., Association between use of dipeptidyl peptidase-4 inhibitors and the risk of acute kidney injury: a nested case-control study. Mayo Clin Proc 91 (2016), 867–872.
Chao, CT, Wang, J, Wu, HY, Chien, KL, Hung, KY., Dipeptidyl peptidase 4 inhibitor use is associated with a lower risk of incident acute kidney injury in patients with diabetes. Oncotarget 8 (2017), 53028–53040.
Lo Re, V, Carbonari, DM, Saine, ME, Newcomb, CW, Roy, JA, Liu, Q, et al. Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ Open Diabetes Res Care, 5, 2017, e000400.
Scheen, AJ, Delanaye, P., Renal outcomes with dipeptidyl peptidase-4 inhibitors. Diabetes Metab 44 (2018), 101–111.
Delanaye, P, Scheen, AJ., Preventing and treating kidney disease in patients with type 2 diabetes. Expert Opin Pharmacother 20 (2019), 277–294.
Iskander, C, Cherney, DZ, Clemens, KK, Dixon, SN, Harel, Z, Jeyakumar, N, et al. Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study. CMAJ 192 (2020), E351–EE60.
Pasternak, B, Wintzell, V, Melbye, M, Eliasson, B, Svensson, AM, Franzen, S, et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: scandinavian cohort study. BMJ, 369, 2020, m1186.
Scheen, AJ., Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease. Expert Opin Drug Safety 19 (2020), 243–256.
Milder, TY, Stocker, SL, Day, RO, Greenfield, JR., Potential safety issues with use of sodium-glucose cotransporter 2 inhibitors, particularly in people with type 2 diabetes and chronic kidney disease. Drug Saf 43 (2020), 1211–1221.
Bae, JH, Park, EG, Kim, S, Kim, SG, Hahn, S, Kim, NH., Comparative renal effects of dipeptidyl peptidase-4 inhibitors and sodium-glucose cotransporter 2 inhibitors on individual outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. Endocrinol Metab (Seoul) 36 (2021), 388–400.
Yang, W, Cai, X, Han, X, Ji, L, DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev 32 (2016), 391–404.
Grenet, G, Mekhaldi, S, Mainbourg, S, Auffret, M, Cornu, C, Cracowski, JL, et al. DPP-4 inhibitors and respiratory infection: a systematic review and meta-analysis of the cardiovascular outcomes trials. Diabetes Care, 44, 2021 e36-e7.
Morieri, ML, Bonora, BM, Longato, E, Di Camilo, B, Sparacino, G, Tramontan, L, et al. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis. Diabetes Obes Metab 22 (2020), 1925–1934.
Scheen, AJ., DPP-4 inhibition and COVID-19: from initial concerns to recent expectations. Diabetes Metab, 47, 2021, 101213.
Scheen, AJ., SGLT2 inhibition during the COVID-19 epidemic: friend or foe?. Diabetes Metab 46 (2020), 343–344.
Imatoh, T, Nishi, T, Yasui, M, Maeda, T, Sai, K, Saito, Y, et al. Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: a retrospective cohort study. Pharmacoepidemiol Drug Saf 27 (2018), 931–939.
Raji, A, Xu, ZJ, Lam, RLH, O'Neill, EA, Kaufman, KD, Engel, SS., Efficacy and safety of sitagliptin compared with dapagliflozin in people >/= 65 years old with type 2 diabetes and mild renal insufficiency. Diabetes Ther 11 (2020), 2419–2428.
Lega, IC, Bronskill, SE, Campitelli, MA, Guan, J, Stall, NM, Lam, K, et al. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: a population-based study of older women and men with diabetes. Diabetes Obes Metab 21 (2019), 2394–2404.
Wang, M, Zhang, X, Ni, T, Wang, Y, Wang, X, Wu, Y, et al. Comparison of new oral hypoglycemic agents on risk of urinary tract and genital infections in type 2 diabetes: a network meta-analysis. Adv Ther 38 (2021), 2840–2853.
Bonnet, F, Scheen, A., Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab 19 (2017), 473–481.
Scheen, A., Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis. Expert Opin Drug Saf 12 (2013), 545–557.
Singh, AK, Gangopadhyay, KK, Singh, R., Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Rev Clin Pharmacol 13 (2020), 461–468.
Scheen, AJ., Alogliptin: concern about hepatotoxicity?. Clin Pharmacokinet 53 (2014), 1057–1059.
Mantovani, A, Targher, G, Zoppini, G., Nonalcoholic fatty liver disease and implications for older adults with diabetes. Clin Geriatr Med 36 (2020), 527–547.
Dos Santos, LR, Duarte, ML, Peccin, MS, Gagliardi, ART, Melnik, T, Dipeptidyl peptidase IV inhibitors for nonalcoholic fatty liver disease - Systematic review and metanalysis. Curr Diabetes Rev, 17, 2021: e101120187811.
Dougherty, JA, Guirguis, E, Thornby, KA., A systematic review of newer antidiabetic agents in the treatment of nonalcoholic fatty liver disease. Ann Pharmacother 55 (2021), 65–79.
Scheen, AJ., Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: a common comorbidity associated with severe complications. Diabetes Metab 45 (2019), 213–223.
Mantovani, A, Petracca, G, Csermely, A, Beatrice, G, Targher, G., Sodium-glucose cotransporter-2 inhibitors for treatment of nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Metabolites, 11, 2020, 22, 10.3390/metabo11010022.
Adil, M, Khan, RA, Kalam, A, Venkata, SK, Kandhare, AD, Ghosh, P, et al. Effect of anti-diabetic drugs on bone metabolism: evidence from preclinical and clinical studies. Pharmacol Rep 69 (2017), 1328–1340.
Wolverton, D, Blair, MM., Fracture risk associated with common medications used in treating type 2 diabetes mellitus. Am J Health Syst Pharm 74 (2017), 1143–1151.
Yang, Y, Zhao, C, Liang, J, Yu, M, Qu, X., Effect of dipeptidyl peptidase-4 inhibitors on bone metabolism and the possible underlying mechanisms. Front Pharmacol, 8, 2017, 487.
Mamza, J, Marlin, C, Wang, C, Chokkalingam, K, Idris, I., DPP-4 inhibitor therapy and bone fractures in people with Type 2 diabetes – a systematic review and meta-analysis. Diabetes Res Clin Pract 116 (2016), 288–298.
Fu, J, Zhu, J, Hao, Y, Guo, C, Zhou, Z., Dipeptidyl peptidase-4 inhibitors and fracture risk: an updated meta-analysis of randomized clinical trials. Sci Rep, 6, 2016, 29104.
Josse, RG, Majumdar, SR, Zheng, Y, Adler, A, Bethel, MA, Buse, JB, et al. Sitagliptin and risk of fractures in type 2 diabetes: results from the TECOS trial. Diabetes Obes Metab 19 (2017), 78–86.
Driessen, JH, van den Bergh, JP, van Onzenoort, HA, Henry, RM, Leufkens, HG, de Vries, F., Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. Diabetes Obes Metab 19 (2017), 421–428.
Dombrowski, S, Kostev, K, Jacob, L., Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data. Osteoporos Int 28 (2017), 2421–2428.
Carbone, LD, Buzkova, P, Fink, HA, Robbins, JA, Bethel, M, Isales, CM, et al. Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study. Osteoporos Int 28 (2017), 1631–1640.
Men, P, He, N, Song, C, Zhai, S., Dipeptidyl peptidase-4 inhibitors and risk of arthralgia: a systematic review and meta-analysis. Diabetes Metab 43 (2017), 493–500.
Erythropoulou-Kaltsidou, A, Polychronopoulos, G, Tziomalos, K., Sodium-glucose co-transporter 2 inhibitors and fracture risk. Diabetes Ther 11 (2020), 7–14.
Li, X, Li, T, Cheng, Y, Lu, Y, Xue, M, Xu, L, et al. Effects of SGLT2 inhibitors on fractures and bone mineral density in type 2 diabetes: an updated meta-analysis. Diabetes Metab Res Rev, 35, 2019, e3170.
Qian, BB, Chen, Q, Li, L, Yan, CF., Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporos Int 31 (2020), 2313–2320.
Adimadhyam, S, Lee, TA, Calip, GS, Smith Marsh, DE, Layden, BT, Schumock, GT, Sodium-glucose co-transporter 2 inhibitors and the risk of fractures: a propensity score-matched cohort study. Pharmacoepidemiol Drug Saf 28 (2019), 1629–1639.
Bene, J, Moulis, G, Bennani, I, Auffret, M, Coupe, P, Babai, S, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database. Br J Dermatol 175 (2016), 296–301.
Lee, H, Chung, HJ, Pawar, A, Patorno, E, Kim, DH., Evaluation of risk of bullous pemphigoid with initiation of dipeptidyl peptidase-4 inhibitor vs second-generation sulfonylurea. JAMA Dermatol 156 (2020), 1107–1114.
Hung, CT, Liu, JS, Cheng, CY, Chung, CH, Chiang, CP, Chien, WC, et al. Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: a nationwide, population-based, cohort study in Taiwan. J Dermatol 47 (2020), 245–250.
Sun, L, Wang, C, Wu, C, Zhou, Y, Wang, C., Analysis of the clinical characteristics of dipeptidyl peptidase-4 inhibitor-induced bullous pemphigoid. Ann Pharmacother, Epub, 2021, 10600280211022722.
Dicembrini, I, Montereggi, C, Nreu, B, Mannucci, E, Monami, M., Pancreatitis and pancreatic cancer in patientes treated with Dipeptidyl Peptidase-4 inhibitors: an extensive and updated meta-analysis of randomized controlled trials. Diabetes Res Clin Pract, 159, 2020, 107981.
Jabbour, S, Seufert, J, Scheen, A, Bailey, CJ, Karup, C, Langkilde, AM., Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes Metab 20 (2018), 620–628.
Dicembrini, I, Nreu, B, Mannucci, E, Monami, M., Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: a meta-analysis of randomized controlled trials. Diabetes Obes Metab 21 (2019), 1871–1877.
Tang, H, Dai, Q, Shi, W, Zhai, S, Song, Y, Han, J., SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials. Diabetologia 60 (2017), 1862–1872.
Garcia, M, Arteche-Martinez, U, Lertxundi, U, Aguirre, C., SGLT2 inhibitors and bladder cancer: analysis of cases reported in the European Pharmacovigilance Database. J Clin Pharmacol 61 (2021), 187–192.
Doucet, J, Verny, C, Balkau, B, Scheen, AJ, Bauduceau, B., Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: the GERODIAB observational cohort. Diabetes Metab 44 (2018), 465–472.
Schott, G, Martinez, YV, Ediriweera de Silva, RE, Renom-Guiteras, A, Vogele, A, Reeves, D, et al. Effectiveness and safety of dipeptidyl peptidase 4 inhibitors in the management of type 2 diabetes in older adults: a systematic review and development of recommendations to reduce inappropriate prescribing. BMC Geriatr, 17, 2017, 226.
Kambara, T, Shibata, R, Osanai, H, Nakashima, Y, Asano, H, Sakai, K, et al. Use of sodium-glucose cotransporter 2 inhibitors in older patients with type 2 diabetes mellitus. Geriatr Gerontol Int 18 (2018), 108–114.
Mikhail, N., Use of sodium-glucose cotransporter type 2 inhibitors in older adults with type 2 diabetes mellitus. South Med J 108 (2015), 91–96.
Scheen, AJ., DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects. Expert Opin Drug Metab Toxicol 12 (2016), 1407–1417.
Lingvay, I., Sodium glucose cotransporter 2 and dipeptidyl peptidase-4 inhibition: promise of a dynamic duo. Endocr Pract 23 (2017), 831–840.
van Baar, MJB, van Ruiten, CC, Muskiet, MHA, van Bloemendaal, L, IJ, RG, van Raalte, DH., SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management. Diabetes Care 41 (2018), 1543–1556.